Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.05 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 3.05 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 02/9/2024 | 06:00 | UK RNS | AIM Cancellation - ReNeuron Group Plc |
| 30/8/2024 | 06:00 | UK RNS | ReNeuron Group plc Corporate update and AIM cancellation |
| 02/8/2024 | 11:25 | UK RNS | ReNeuron Group plc Corporate Update |
| 26/6/2024 | 14:33 | UK RNS | ReNeuron Group plc Change of Registered Address |
| 05/6/2024 | 14:36 | UK RNS | ReNeuron Group plc Creditor’s decision on Administrators' Proposals |
| 17/5/2024 | 18:59 | ALNC |  IN BRIEF: ReNeuron administrators in talks with potential investors |
| 17/5/2024 | 17:55 | ALNC | TRADING UPDATES: PetroTal buys Peru's Block 131 for USD5.0 million |
| 17/5/2024 | 11:45 | UK RNS | ReNeuron Group plc Publication of Joint Administrators' Proposals |
| 08/5/2024 | 06:00 | UK RNS | ReNeuron Group plc Update on Administration Process |
| 17/4/2024 | 10:58 | ALNC | ReNeuron CFO steps down to pursue other opportunities |
Reneuron (RENE) Share Charts1 Year Reneuron Chart |
|
1 Month Reneuron Chart |
Intraday Reneuron Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 03/9/2024 | 09:13 | ReNeuron - a leading, clinical-stage stem cell business | 8,647 |
| 20/3/2024 | 14:22 | Rene on the road to recovery. You have been warned BUY BUY BUY switch is on | 251 |
| 28/10/2021 | 10:40 | Interesting article...albeit lengthly | 6 |
| 10/6/2021 | 09:30 | New Chief Scientific Officer | 2 |
| 17/10/2019 | 14:33 | RENE - No revenues, no approvals, rising salaries and loads of dilution | 8 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 02/9/2024 07:22 by luckyabbeygale At least ig are keeping the last trading price for Rene. As it not taken the loss out on the cfds but already has months ago with the spread bets. |
Posted at 30/8/2024 10:06 by luckyabbeygale Surely ig be giving money back instead of putting rene as 0 next Monday. As the law states that bets are protected from this sort of thing. |
Posted at 30/8/2024 06:20 by luckyabbeygale I do not understand how they taken out all the money for Rene from my spreadbet account in advance. When the law covers you if the share goes to 0. |
Posted at 23/7/2024 07:36 by luckyabbeygale I have these on my spread bet account so it be the last price will count since it is limited risk.Otherwise it will be taken from my Oriole funds and then I will be going to the FCA. |
Posted at 17/6/2024 19:52 by thiopia £2m cash + a potential £1m claim on IP milestone gives almost 5p a share of Net Asset Value per Share ?Will be interesting what price the Cornerstone Investor will want though. |
Posted at 21/5/2024 08:11 by thiopia davey50Posts: 3,549 Price: 3.275 No Opinion RE: Lets face it. 17 May 2024 13:12 That amount is more than current market cap, minus fees and lots taking a slice but there surely must be a return here and a decent % of the current valuation the shares were suspended at Cash at Bank RGP held a number of bank accounts and the Joint Administrators have realised £1,956,529.70 in this regard. This figure includes a balance held in USD, which has been converted to GBP using Bank of England rates as at the date of Administration. |
Posted at 20/5/2024 21:07 by thiopia 17 May 2024ReNeuron Group plc ("ReNeuron" or the "Company") Publication of Joint Administrators' Proposals ReNeuron Group plc (in administration) (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that Mark Smith and Stephen Cork of Cork Gully LLP, joint administrators of the Company and of its subsidiaries, ReNeuron Limited, ReNeuron (UK) Limited ReNeuron Holdings Limited (together the "Group") (all in administration) have issued their statement of proposals to the members and creditors of the Group in accordance with the Insolvency Act 1986 and the Insolvency Rules (the "Proposals"). The contents of the main body of the Proposals (without appendices) are set out below without material amendment. A hard copy of the Proposals, including appendices, can be obtained upon request by contacting the joint administrators using the details noted below. Purpose of the Administrations The purpose of the Administrations is to, in the first instance, rescue the Group as a going concern. Should the above not be achievable, the Joint Administrators will seek to achieve a better result for the Company's creditors as a whole than would be likely if the Group were wound up (without first being in Administration). Should both of the above objectives fail, the Joint Administrators will take steps to realise assets in order to make a distribution to one or more preferential creditors. Joint Administrators' strategy The Joint Administrators are progressing negotiations with investor(s) to allow for continuity of the Group's operations. Alternatively, an acquisition of all or part of the Group, or its business and/or assets, is also being explored. The Joint Administrators have sought to preserve value for a prospective investor or purchaser by retaining key employees and ensuring the continuation of critical services. |
Posted at 05/2/2024 14:33 by tomboyb 5 February 2024ReNeuron Group plc ("ReNeuron", the "Group" or the "Company") Corporate update and suspension of trading on AIM ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, provides the following update in relation to its current business development, financing discussions and working capital position. On 8 November 2023, the Group announced its Interim Results for the six months ended 30 September 2023 ("Interim Results"). At the time, the Board stated that the outlook for the business remained positive provided it could retain its' highly dedicated team of scientists, further develop and verify the CustomEX™ exosome delivery platform and conclude validating industry partnerships. As also announced in the Interim Results, potential corporate actions that were under consideration by the Board included raising additional equity financing and/or securing a financing facility and/or entering into M&A discussions. The Group also noted in the Interim Results that as at 30 September 2023, the Group had cash, cash equivalents and bank deposits of £5.1 million and that the Group's latest internal projections (assuming no new revenues or funding) meant there was a cash runway to April 2024, ahead of which point further revenues and/or a capital injection would be required. In the intervening period, despite great scientific progress having been made in further developing and exemplifying the CustomEX™ exosome delivery platform and progressing several ongoing third-party business development discussions, the Group has not yet been able to conclude a validating, revenue generating industry partnership nor been able to secure additional equity funding. Accordingly, throughout the period the Group has been carefully managing its working capital, but it is now in a highly constrained financial position and requires additional financing urgently, in order to continue as a going concern. In the absence of any additional financing being available in the immediate term, the Group now needs to take steps to preserve and maximise value for its creditors. Whilst the Group continues to explore a number of corporate options, including seeking to realise value for its physical and intellectual assets, the Board recognises that in the absence of an immediate injection of capital and in view of the current financial uncertainty, it needs to put staff at risk of redundancy, initiate discussions with its creditors and establish the precise solvency status of the business. Should the Company fail to achieve a solution in the short term, the Board would have no option but to place the Company into administration. Should administrators be appointed, it is not known how much, if any, value would be returned to shareholders. In light of the above, the Company has requested a suspension of trading in its ordinary shares on AIM pending clarification of its financial position. Trading in the Company's ordinary shares has been suspended at 2:30 p.m. today and further updates will be provided in due course. Enquiries: |
Posted at 01/9/2023 14:09 by thiopia RENE ReneuronShare Price : 9.25p Shares o/s : 57.17m Mkt Cap : £5.3m Annual Report (y/e Mar 2023) "Cash, cash equivalents and bank deposits at 31 March 2023 of £7.2 million" " Executive Chairman, Iain Ross, commented: “ I remain very excited about the Company’s potential as we are on course to generate validating data which would allow us to complete partnering and license deals in the coming year which will transform the Company.” Data due September/October ( In vivo studies to generate data to further validate the cellular and tissue targeting capabilities and subsequent functional delivery of therapeutic payloads using the CustomEXTM platform are ongoing. Favourable in vivo data will allow the Group to differentiate its exosome platform and progress ongoing partnering and licensing discussions. The Board has identified a number of potential sources of revenue and non-dilutive funding in order to maintain the business as a going concern and is confident it will be able to conclude third party transactions and/or issue new equity as required. Such transactions will further strengthen and differentiate our exosomes platform, highlighting our potential leadership in the field. Technology Overview ReNeuron’s stem cell derived proprietary exosome technology platform CustomEX™ offers a delivery mechanism for a variety of potential payloads that could include siRNA, mRNA, proteins, small molecules and genes. What are exosomes? l Naturally occurring biological nano particles produced by every cell to mediate intercellular communication. l Can encapsulate various biological molecules within their lipid bilayer membrane or within the lumen of the Exosome. l Can be engineered to deliver drug cargos to target cells, offering an opportunity to treat diseases. The benefits of exosomes l Proven ability to carry and deliver a variety of cargos including proteins and nucleic acids. l Potential to deliver more than one bio-active cargo simultaneously. l Target recipient cells via specific surface proteins that are determined by their cell of origin. l Low or no immunogenicity, thereby evading immune detection. Current delivery mechanisms have limitations l Viral vectors have been plagued by side effect issues and high costs, limitation on the type and size of cargo they can deliver. l Lipid nanoparticles (LNPs) have no natural tissue and cell targeting capabilities with delivery therefore untargeted and mainly to the liver. l Both have immunogenetic properties that can be problematic. CustomExTM: A customisable exosome platform l Seven proprietary conditionally immortalised* exosome producer stem cell lines producing unique exosome populations. l ReNeuron’s iPSC platform allows production of exosomes that have the functional properties based on parent stem cells. l Capable of delivering a variety of payloads including proteins and nucleic acids and the next generation for delivery of gene editing technologies. l Data highlights increased uptake and delivery of payload when compared to a conventional HEK exosome approach. l Our CustomExTM exosomes have distinct surface marker profiles (tropisms) enabling a greater tissue targeting capability. *Conditional immortalisation of stem cell exosome producer lines offers an elegant solution to not only consistently produce cell lines that are genetically stable and can be grown at scale, but also to produce a high yielding source of consistent exosomes for the delivery of complex drug modalities. The standard approach used by our competitors is to produce exosomes from a single generic cell line. A one-size-fits-all approach. A single cell line, giving rise to a single outcome. CSO Randolph Corteling delivering Seminar Presentation in Boston due September 6th |
Posted at 19/8/2023 23:02 by thiopia ("ReNeuron" or the "Company")Notice of Annual General Meeting ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , announces that the Notice of Annual General Meeting ("AGM") and Form of Proxy have today been posted to shareholders and will shortly be available on the investors section of the Company's website here . The AGM will be held at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate, London EC2N 4BQ on 22 August 2023 at 9.30 a.m. The Board welcomes the opportunity to invite shareholders to attend the AGM in person. Persons intending to attend and vote at the meeting in person will need a QR code to access the meeting venue. Such QR code will need to be displayed on a smartphone or similar device. A QR code will be able to be obtained in advance by emailing externalproxyqueries If shareholders are unable to attend the meeting in person, then they are encouraged to submit their votes by proxy by appointing the Chairman of the AGM as their proxy, so that their votes can be taken into account. Shareholders are also encouraged to submit any questions for the Chairman to info@reneuron.com at least 48 hours prior to the Meeting. Shareholders that are able to attend the AGM in person will also have an opportunity to ask questions at the Meeting. Where appropriate, questions and answers will be collated and later published on the Company's website at www.reneuron.com. The results of the proposed resolutions will be published on the Company website and announced via RNS as soon as practicable after the conclusion of the AGM. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
